Diao Yu-Hang, Rao Si-Qi, Shu Xin-Peng, Cheng Yong, Tan Can, Wang Li-Juan, Peng Dong
Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
World J Gastrointest Surg. 2024 May 27;16(5):1344-1353. doi: 10.4240/wjgs.v16.i5.1344.
Preoperative serum tumor markers not only play a role in the auxiliary diagnosis and postoperative monitoring in colorectal cancer (CRC), but also have been found to have potential prognostic value.
To analyze whether preoperative serum tumor markers, including carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9), affect the prognosis of CRC.
This was a retrospective study conducted in a single center. Patients with nonmetastatic CRC who underwent initial surgery between January 2011 and January 2020 were enrolled and divided into development site and validation site groups at a ratio of 7:3. The independent prognostic factors were screened by Cox regression analysis, and finally, a prognostic nomogram model was established. The newly developed model was tested by internal validation.
Eventually, 3526 postoperative patients with nonmetastatic CRC were included in the study. There were 2473 patients at the development site and 1056 patients at the validation site. Age ( < 0.01, HR = 1.042, 95%CI = 1.033-1.051), tumor node metastasis (TNM) classification ( < 0.01, HR = 1.938, 95%CI = 1.665-2.255), preoperative CEA ( = 0.001, HR = 1.393, 95%CI = 1.137-1.707) and CA19-9 ( < 0.01, HR = 1.948, 95%CI = 1.614-2.438) levels were considered independent prognostic factors for patients with nonmetastatic CRC and were used as variables in the nomogram model. The areas under the curve of the development and validation sites were 0.655 and 0.658, respectively. The calibration plot also showed the significant performance of the newly established nomogram.
We successfully constructed a nomogram model based on age, TNM stage, preoperative CEA, and CA19-9 levels to evaluate the overall survival of patients with nonmetastatic CRC.
术前血清肿瘤标志物不仅在结直肠癌(CRC)的辅助诊断和术后监测中发挥作用,而且已被发现具有潜在的预后价值。
分析术前血清肿瘤标志物,包括癌胚抗原(CEA)和糖类抗原19-9(CA19-9),是否影响CRC的预后。
这是一项在单一中心进行的回顾性研究。纳入2011年1月至2020年1月期间接受初次手术的非转移性CRC患者,并按7:3的比例分为开发组和验证组。通过Cox回归分析筛选独立预后因素,最终建立预后列线图模型。通过内部验证对新开发的模型进行测试。
最终,3526例术后非转移性CRC患者纳入研究。开发组有2473例患者,验证组有1056例患者。年龄(<0.01,HR = 1.042,95%CI = 1.033 - 1.051)、肿瘤淋巴结转移(TNM)分类(<0.01,HR = 1.938,95%CI = 1.665 - 2.255)、术前CEA(=0.001,HR = 1.393,95%CI = 1.137 - 1.707)和CA19-9(<0.01,HR = 1.948,95%CI = 1.614 - 2.438)水平被认为是非转移性CRC患者的独立预后因素,并用作列线图模型中的变量。开发组和验证组的曲线下面积分别为0.655和0.658。校准图也显示了新建立的列线图的显著性能。
我们成功构建了一个基于年龄、TNM分期、术前CEA和CA19-9水平的列线图模型,以评估非转移性CRC患者的总生存期。